Drug Interaction Potential Clinical Trial
Official title:
An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients
| Verified date | April 2021 |
| Source | Daiichi Sankyo, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents. Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types. In Part 2, the same participants will continue to receive pexidartinib twice daily. Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.
| Status | Completed |
| Enrollment | 32 |
| Est. completion date | April 16, 2021 |
| Est. primary completion date | September 26, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Is the age of majority in country of residence - Has a diagnosis of: 1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations and for whom surgery is not an option (prior pexidartinib is permitted for TGCT patients unless ineffective or not tolerated and there has been a washout period of at least 4 weeks) 2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST), for which there is no standard systemic therapy, or 3. other solid tumors (all comers) for which there is no standard systemic therapy and there is a rationale for use of pexidartinib at the Investigator's discretion - If a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 hours before enrollment where required - Is a non-sterile male or female willing to use of one of the protocol-defined highly effective contraception methods: 1. intra-uterine device (nonhormonal or hormonal) 2. sexual abstinence (only if this is in line with the patient's current lifestyle) 3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods associated with inhibition of ovulation - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at least 50 years of age, with a follicle-stimulating hormone level > 40 milli-International units per mL (mIU/mL) - Has adequate hematologic, hepatic, and renal function as defined by the protocol - Is able and willing to follow all study procedures - Has provided a signed informed consent Exclusion Criteria: - Is pregnant or breastfeeding - Is unable to swallow oral medication - Is unable to follow study procedures - Is taking or has taken any medications or therapies outside of protocol-defined parameters - Has any disease or condition that, per protocol or in the opinion of the investigator, might affect: 1. safety and well-being of the participant or offspring 2. safety of study staff 3. analysis of results |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | Leids Universitair Medisch Centrum | Leiden | |
| New Zealand | Christchurch Hospital NZ | Christchurch | |
| Taiwan | National Taiwan University Hospital | Taipei | |
| United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
| United States | Mary Crowley Cancer Research | Dallas | Texas |
| United States | Karmanos Cancer Center | Detroit | Michigan |
| United States | Northwell Health | Lake Success | New York |
| United States | Stanford University | Palo Alto | California |
| United States | HonorHealth | Scottsdale | Arizona |
| United States | University of Arizona | Tucson | Arizona |
| United States | University of Kansas Cancer Center | Westwood | Kansas |
| Lead Sponsor | Collaborator |
|---|---|
| Daiichi Sankyo, Inc. |
United States, Netherlands, New Zealand, Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Pharmacokinetic Analysis: Maximum Concentration (Cmax) for Midazolam | Plasma samples for midazolam were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 hours (h) (±10 minutes up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). | Baseline to 15 days post treatment | |
| Primary | Pharmacokinetic Analysis: Maximum Concentration (Cmax) for Tolbutamide | Plasma samples for tolbutamide were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (±10 min up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). | Baseline to 15 days post treatment | |
| Primary | Pharmacokinetic Analysis: Time to Maximum Concentration (Tmax) for Midazolam | Plasma samples for midazolam were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 hours (h) (±10 minutes up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). | Baseline to 15 days post treatment | |
| Primary | Pharmacokinetic Analysis: Time to Maximum Concentration (Tmax) for Tolbutamide | Plasma samples for tolbutamide were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (±10 min up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). | Baseline to 15 days post treatment | |
| Primary | Pharmacokinetic Analysis: Area Under the Curve to the Last Observable Concentration (AUClast) for Midazolam | Plasma samples for midazolam were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 hours (h) (±10 minutes up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). | Baseline to 15 days post treatment | |
| Primary | Pharmacokinetic Analysis: Area Under the Curve to the Last Observable Concentration (AUClast) for Tolbutamide | Plasma samples for tolbutamide were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (±10 min up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). | Baseline to 15 days post treatment | |
| Primary | Overall Summary of Treatment-emergent Adverse Events | Adverse events that emerge during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. | Baseline to 1 year post treatment | |
| Secondary | Pharmacokinetic Analysis: Maximum Concentration (Cmax) for Pexidartinib and ZAAD-1006a Metabolite | Plasma samples for pexidartinib and its metabolite were collected at predose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, and 10 (±1) h after the first dose on Day 3, and at steady state when co-administered with midazolam and tolbutamide on Day 13. | Baseline to 13 days post treatment | |
| Secondary | Pharmacokinetic Analysis: Time to Maximum Concentration (Tmax) for Pexidartinib and ZAAD-1006a Metabolite | Plasma samples for pexidartinib and its metabolite were collected at predose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, and 10 (±1) h after the first dose on Day 3, and at steady state when co-administered with midazolam and tolbutamide on Day 13. | Baseline to 13 days post treatment | |
| Secondary | Pharmacokinetic Analysis: Area Under the Curve to the Last Observable Concentration (AUClast) for Pexidartinib and ZAAD-1006a Metabolite | Plasma samples for pexidartinib and its metabolite were collected at predose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, and 10 (±1) h after the first dose on Day 3, and at steady state when co-administered with midazolam and tolbutamide on Day 13. | Baseline to 13 days post treatment | |
| Secondary | Pharmacokinetic Analysis: Maximum Concentration (Cmax) for Midazolam Metabolite, 1-Hydroxy Midazolam | Plasma samples for midazolam and 1-hydroxy midazolam were to be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 (±10 min up to 8 h), 10 (±2), 24 (±2), and 48 (±2) hours on Days 1 to 3 and also when co-administered with pexidartinib on Days 3 to 5 and Days 13 to 15. | Baseline to 13 days post treatment | |
| Secondary | Pharmacokinetic Analysis: Time to Maximum Concentration (Tmax) for Midazolam Metabolite, 1-Hydroxy Midazolam | Plasma samples for midazolam and 1-hydroxy midazolam were to be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 (±10 min up to 8 h), 10 (±2), 24 (±2), and 48 (±2) hours on Days 1 to 3 and also when co-administered with pexidartinib on Days 3 to 5 and Days 13 to 15. | Baseline to 13 days post treatment | |
| Secondary | Pharmacokinetic Analysis: Area Under the Curve to the Last Observable Concentration (AUClast) for Midazolam Metabolite, 1-Hydroxy Midazolam | Plasma samples for midazolam and 1-hydroxy midazolam were to be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 (±10 min up to 8 h), 10 (±2), 24 (±2), and 48 (±2) hours on Days 1 to 3 and also when co-administered with pexidartinib on Days 3 to 5 and Days 13 to 15. | Baseline to 13 days post treatment | |
| Secondary | Pharmacokinetic Analysis: Metabolite to Parent Ratio (MPR) for Midazolam | Plasma samples for midazolam were collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 hours (h) (±10 minutes up to 1 h, ±10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15). Plasma pharmacokinetic parameters calculated for Midazolam metabolite. 1-hydroxy midazolam and midazolam for the MPR value. |
Baseline to 13 days post treatment |